MX2021006428A - Anticuerpos anti-claudina 18.2 y anti-4-1bb biespecificos y su uso. - Google Patents

Anticuerpos anti-claudina 18.2 y anti-4-1bb biespecificos y su uso.

Info

Publication number
MX2021006428A
MX2021006428A MX2021006428A MX2021006428A MX2021006428A MX 2021006428 A MX2021006428 A MX 2021006428A MX 2021006428 A MX2021006428 A MX 2021006428A MX 2021006428 A MX2021006428 A MX 2021006428A MX 2021006428 A MX2021006428 A MX 2021006428A
Authority
MX
Mexico
Prior art keywords
claudin
bispecific antibodies
antibodies
signaling
expressing
Prior art date
Application number
MX2021006428A
Other languages
English (en)
Inventor
Lei Fang
Zhengyi Wang
Bingshi Guo
Eunsil Sung
Byungje Sung
Eunyoung Park
Wenqing Jiang
Original Assignee
I Mab Biopharma Us Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by I Mab Biopharma Us Ltd filed Critical I Mab Biopharma Us Ltd
Publication of MX2021006428A publication Critical patent/MX2021006428A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcionan anticuerpos biespecíficos y multiespecíficos que se dirigen tanto a la claudina 18.2 (CLDN18.2) como a la 4-1BB. Estos anticuerpos, en ausencia de células que expresan CLDN18.2, pueden unirse a 4-1BB, pero no pueden activar la señalización de 4- 1BB. Sin embargo, en presencia de células que expresan CLDN18.2, estos anticuerpos pueden desencadenar la señalización 4-1BB dependiente de CLDN18.2, lo que conduce a una potente respuesta inmune a las células tumorales que expresan CLDN18.2.
MX2021006428A 2019-08-12 2020-08-12 Anticuerpos anti-claudina 18.2 y anti-4-1bb biespecificos y su uso. MX2021006428A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2019100162 2019-08-12
CN2019104508 2019-09-05
CN2020071954 2020-01-14
CN2020087968 2020-04-30
PCT/CN2020/108707 WO2021027850A1 (en) 2019-08-12 2020-08-12 Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2021006428A true MX2021006428A (es) 2021-11-17

Family

ID=74570528

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006428A MX2021006428A (es) 2019-08-12 2020-08-12 Anticuerpos anti-claudina 18.2 y anti-4-1bb biespecificos y su uso.

Country Status (16)

Country Link
US (2) US11261259B2 (es)
EP (1) EP3853257A4 (es)
JP (2) JP7410141B2 (es)
KR (1) KR20210082482A (es)
CN (1) CN113166265A (es)
AU (1) AU2020329466A1 (es)
BR (1) BR112021008870A2 (es)
CA (1) CA3117740A1 (es)
CL (1) CL2021001375A1 (es)
CO (1) CO2021006953A2 (es)
IL (1) IL283379A (es)
MX (1) MX2021006428A (es)
PE (1) PE20211147A1 (es)
PH (1) PH12021551269A1 (es)
SG (1) SG11202104131VA (es)
WO (1) WO2021027850A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4004053A4 (en) * 2019-07-26 2023-10-18 ABL Bio, Inc. BISPECIFIC ANTI-EGFR/ANTI-4-1BB ANTIBODIES AND USE THEREOF
CA3229014A1 (en) * 2021-08-18 2023-02-23 Yi Luo Bispecific antibody and use thereof
CN116410326A (zh) * 2021-12-30 2023-07-11 三优生物医药(上海)有限公司 抗cd40×cldn18.2双特异性抗体及其用途
WO2023134657A1 (zh) * 2022-01-11 2023-07-20 原启生物科技(上海)有限责任公司 抗cldn18.2和4-1bb的双特异性抗原结合蛋白及其用途
WO2023222135A1 (en) * 2022-05-20 2023-11-23 I-Mab Biopharma Co., Ltd. A method of treating solid tumor
WO2023232140A1 (en) * 2022-06-03 2023-12-07 Lanova Medicines Development Co., Ltd. Cancer treatment with a pd-1 or pd-l1 inhibitor and an antibody-drug conjugates targeting claudin 18.2

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
WO2014075697A1 (en) 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
CN105073776B (zh) * 2012-11-13 2019-04-12 拜恩科技股份公司 用于治疗表达紧密连接蛋白的癌症疾病的制剂
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
EP3099706B1 (en) * 2014-01-29 2018-10-31 BioNTech AG Peptide mimotopes of claudin 18.2 and uses thereof
IL260983B (en) * 2016-02-19 2022-07-01 Genisphere Llc Nucleic acid carriers and methods of medical use
WO2018114754A1 (en) 2016-12-19 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy with targeted 4-1bb (cd137) agonists
WO2018119001A1 (en) 2016-12-19 2018-06-28 Fred Hutchinson Cancer Research Center Peptide-antibody compositions and methods of use thereof
JP7247091B2 (ja) 2016-12-20 2023-03-28 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ２０／抗ｃｄ３二重特異性抗体と４－１ｂｂ（ｃｄ１３７）アゴニストの併用療法
JP7122311B2 (ja) * 2017-01-03 2022-08-19 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗４－１ｂｂクローン２０ｈ４．９を含む二重特異性抗原結合分子
US20190336615A1 (en) 2017-01-27 2019-11-07 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
CA3082321A1 (en) * 2017-11-13 2019-05-16 Crescendo Biologics Limited Single domain antibodies that bind to cd137
MX2021006379A (es) * 2018-11-30 2021-10-13 Abl Bio Inc Anticuerpos biespecificos anti-pd-l1/anti-4-1bb y usos de los mismos.
WO2021101346A1 (en) * 2019-11-21 2021-05-27 Dong-A St Co., Ltd. Anti-ror1/anti-4-1bb bispecific antibodies and uses thereof
WO2021097800A1 (en) * 2019-11-22 2021-05-27 Abl Bio Inc. Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof

Also Published As

Publication number Publication date
AU2020329466A1 (en) 2021-05-27
PH12021551269A1 (en) 2021-11-03
US20210317224A1 (en) 2021-10-14
CO2021006953A2 (es) 2021-08-19
CL2021001375A1 (es) 2022-01-07
EP3853257A4 (en) 2022-06-29
CA3117740A1 (en) 2021-02-18
US11261259B2 (en) 2022-03-01
EP3853257A1 (en) 2021-07-28
PE20211147A1 (es) 2021-06-28
JP7410141B2 (ja) 2024-01-09
WO2021027850A1 (en) 2021-02-18
JP2022543508A (ja) 2022-10-13
KR20210082482A (ko) 2021-07-05
CN113166265A (zh) 2021-07-23
US20220348675A1 (en) 2022-11-03
IL283379A (en) 2021-07-29
JP2023182853A (ja) 2023-12-26
BR112021008870A2 (pt) 2021-11-30
SG11202104131VA (en) 2021-05-28

Similar Documents

Publication Publication Date Title
PH12021551269A1 (en) Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof
PH12019550147A1 (en) Engineered transferrin receptor binding polypeptides
PH12019501440A1 (en) Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
MX2018014227A (es) Proteinas de union de cadena unica de fragmento variable cd3.
AU2018366199A1 (en) Bispecific and monospecific antibodies using novel anti-PD-1 sequences
ZA202002325B (en) Constrained conditionally activated binding proteins
MY192822A (en) An anti-ctla4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition and use
MX2021002969A (es) Proteinas de union a nkg2d, cd16, y egfr, ccr4 o pd-l1.
WO2018109174A3 (en) Il-11 antibodies
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
AU2019415848A8 (en) Claudin18.2 binding moieties and uses thereof
WO2018151821A8 (en) ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND USES THEREOF
WO2016191643A3 (en) Tigit-binding agents and uses thereof
SG10201803042PA (en) Anti-tim-3 antibodies
EP4273258A3 (en) Proteins binding her2, nkg2d and cd16
MX2020012091A (es) Composiciones anti-cd24 y usos de las mismas.
MX2019009566A (es) Proteinas de union a bcma, nkg2d y cd16.
WO2019086331A3 (en) Bispecific antibodies binding alk-1 and bmpr-2
MX2021013417A (es) Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
MX2021001703A (es) Polipeptidos de union a ox40 y sus usos.
JOP20200295A1 (ar) أجسام أحادية النوعية ومتعددة النوعية مضادة لـ tmeff2 المضاد واستخداماتها
MX2021001129A (es) Metodo de purificacion de antigenos.
MX2019009847A (es) Proteínas que se unen a cd123, nkg2d y cd16.
PH12019550194A1 (en) Anti-ceacam1 antibody and use thereof
MY191745A (en) Efficient selectivity of recombinant proteins